Cell and Gene Therapy: From Disruption to Sustainable Transformation
At a recent Huron round table, experts from across the cell and gene therapy (CGT) landscape discussed the biggest obstacles surrounding CGT and how to surmount them. Participants, who included treatment developers, healthcare providers, payors and policymakers, shared concerns about demonstrating the durability, pricing, access and value of CGT and creating scalable manufacturing and treatment delivery models.
For more insights into these areas (below) and broader insights into the discussions that were had at the round table, please submit your details.
- Clinical development
- Manufacturing and supply chains
- Treatment delivery
- Defining value
- Access and pricing
Receive the latest insights and news from Huron’s transformation experts.